Investment case

Walgreens Boots Alliance, Inc.

WBA · 9 developments mapped · last assessed 2026-09-23

Market Ontology has mapped 9 macro, policy, and market developments to Walgreens Boots Alliance, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for WBA yet, so no modelled value is shown. The WBA valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run WBA on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for WBA. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value WBA on your own assumptions

Run the valuation on Walgreens Boots Alliance, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run WBA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade WBA

Professional

Open trade discovery with Walgreens Boots Alliance, Inc. and WBA already in context.

Open

Find pricing gaps in WBA

Institutional

Open relative-value and arbitrage analysis with WBA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens WBA first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
Increased prescription volume for a high-demand drug, driving pharmacy revenue and foot traffic.
2026-09-18 · Moves pharmacy segment growth rate, prescription volume trends
Main threat
Ulta Beauty, Inc. Announces Second Quarter Fiscal 2026 Results and Acquisition of Space NK
Increased competition in the beauty retail market, particularly for mass-market and accessible luxury segments.
2026-08-27 · Moves beauty segment market share, competitive pressure
Open question
NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses
Potential for increased prescription volume for GLP-1 drugs (both branded and compounded) through its retail pharmacy segment, but also pressure on pharmacy margins if compounded options gain significant traction.
2026-09-01 · Moves pharmacy script volume growth, retail pharmacy margins

What changed, by assumption

Pharmacy segment growth rate

2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

Pharmacy script volume growth

2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses

Increased prescription fulfillment volume

2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly

Pharmacy prescription volume growth

2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push

Prescription volume growth

2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-09-23	Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly	Bullish	1-3m	0.40
2026-09-23	Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push	Bullish	1-3m	0.40
2026-09-18	Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs	mixed	3-12m	0.40
2026-09-18	Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands	Bullish	3-12m	0.60
2026-09-01	NexLife Expands Compounded GLP-1 Pricing at $119-$169 Flat Monthly Fee	mixed	3-12m	0.30
2026-09-01	NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly Tiers	mixed	3-12m	0.30
2026-09-01	NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses	mixed	3-12m	0.50
2026-08-28	Ulta Beauty Q2 net sales reach $3.04B with comparable sales up 3.8%	mixed	1-3m	0.30
2026-08-27	Ulta Beauty, Inc. Announces Second Quarter Fiscal 2026 Results and Acquisition of Space NK	Bearish	3-12m	0.30

Value WBA yourself$399/month

Continue this research

Value WBA on your own assumptions

Run the valuation on Walgreens Boots Alliance, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run WBA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade WBA

Professional

Open trade discovery with Walgreens Boots Alliance, Inc. and WBA already in context.

Open

Find pricing gaps in WBA

Institutional

Open relative-value and arbitrage analysis with WBA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens WBA first, then any listed company you want to value or monitor.

Choose another company

Walgreens Boots Alliance, Inc.

WBA · 9 developments mapped · last assessed 2026-09-23

Value WBA on your own assumptions

Run the valuation on Walgreens Boots Alliance, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run WBA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade WBA

Professional

Open trade discovery with Walgreens Boots Alliance, Inc. and WBA already in context.

Open

Find pricing gaps in WBA

Institutional

Open relative-value and arbitrage analysis with WBA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens WBA first, then any listed company you want to value or monitor.

Choose another company

Date

Mechanism

Direction

Horizon

Impact

2026-09-23

Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly

Bullish

1-3m

0.40

2026-09-23

Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push

Bullish

1-3m

0.40

2026-09-18

Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs

mixed

3-12m

0.40

2026-09-18

Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

Bullish

3-12m

0.60

2026-09-01

NexLife Expands Compounded GLP-1 Pricing at $119-$169 Flat Monthly Fee

mixed

3-12m

0.30

2026-09-01

NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly Tiers

mixed

3-12m

0.30

2026-09-01

NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses

mixed

3-12m

0.50

2026-08-28

Ulta Beauty Q2 net sales reach $3.04B with comparable sales up 3.8%

mixed

1-3m

0.30

2026-08-27

Ulta Beauty, Inc. Announces Second Quarter Fiscal 2026 Results and Acquisition of Space NK

Bearish

3-12m

0.30

Value WBA on your own assumptions

Run the valuation on Walgreens Boots Alliance, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run WBA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade WBA

Professional

Open trade discovery with Walgreens Boots Alliance, Inc. and WBA already in context.

Open

Find pricing gaps in WBA

Institutional

Open relative-value and arbitrage analysis with WBA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens WBA first, then any listed company you want to value or monitor.

Choose another company